Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension

Pfizer

Overview

Aldazide 25 mg OD will be given to Filipino hypertensive patients, and there will be 2 follow-up visits on week 4 and week 8 to monitor for safety and efficacy as primary and secondary outcomes, respectively.

Prospective, non-interventional non-probability sampling

Study Type

OBSERVATIONAL

Conditions

Hypertension

Interventions

AldazideDRUG

Aldazide 25 mg OD

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients \>/= 18 years old with Stage 1 or 2 hypertension not controlled by monotherapy or by a combination of anti-hypertensives without any diuretic yet. Exclusion Criteria: * Pregnant or lactating women, with hypersensitivity to Aldazide, patients with resistant hypertension not controlled by a combination therapy with a diuretic in their regimen

Outcomes

Primary Outcomes

Report of Adverse Events occurence (Safety)

Time frame: 8 weeks

Secondary Outcomes

Systolic BP in mmHg

Time frame: 8 weeks

Diastolic BP in mmHg

Time frame: 8 weeks

% of patients reaching BP goal of <140/90 mmHg and <130/80 mmHg for DM and proteinuric patients

Time frame: 8 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.